Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib

Jie Gao; Shu Liu; Shao-Jun Li; Rui Wang; Zeng-Hui Meng; Xiang-Shuo Kong

doi:10.12659/MSM.944526

21 July 2024 : Clinical Research

Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib

Jie Gao^1BCE, Shu Liu^2BCE, Shao-Jun Li^1BCE, Rui Wang^3E, Zeng-Hui Meng^1AE, Xiang-Shuo Kong^2AE*

DOI: 10.12659/MSM.944526

Med Sci Monit 2024; 30:e944526

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

View HTML version

Figure 1 A Markov model designed for advanced hepatocellular carcinoma (HCC). The model consists of 3 primary health states, represented by ovals. Patients have the potential to transition from the “progression-free disease (PFD)” state to either the “progressed disease (PD)” state or the “death” state.

Back to the Article

Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib

Your Privacy